Details

Hopantenic acid tablets 250mg, No. 50

cognitive impairment in organic brain lesions, including the consequences of neuroinfections, craniocerebral trauma and neurotic disorders;

extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system in combination with ongoing therapy;

as a corrector for side effects of neuroleptic drugs, with neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of complex therapy for cerebral organic insufficiency in patients with schizophrenia; epilepsy with a slowdown in mental processes in complex therapy with anticonvulsants;

psycho-emotional overload, decreased mental and physical performance, to improve concentration and memorization;

neurogenic urinary disorders (Pollakiuria, urgency, urinary incontinence, enuresis);

children with developmental delay (mental, speech, motor or their combination), including against the background of previous perinatal encephalopathy and in children with various forms of cerebral palsy;

children with hyperkinetic disorders (attention deficit hyperactivity disorder);

children with neurosis-like conditions (tics, stuttering, mainly with a clonic form).

Inside, 15-30 minutes after eating. A single dose for adults is usually 250-1000 mg, for children - 250-500 mg; the daily dose for adults is 1500-3000 mg, for children - 750-3000 mg.

The course of treatment is from 1 to 4 months, in some cases up to 6 months. A second course of treatment is possible in 3-6 months.

For cognitive impairment with organic brain lesions, including the consequences of neuroinfections, traumatic brain injuries and neurotic disorders: 250 mg 3-4 times a day.

With extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system, in combination with ongoing therapy: at a dose of 500 to 3000 mg per day. The course of treatment is up to 4 months or more.

As a corrector for side effects of neuroleptic drugs, with neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of complex therapy for cerebral organic insufficiency in patients with schizophrenia: adults - at a dose of 500 to 1000 mg 3 times a day; children - in a dose of 250 to 500 mg 3-4 times a day. The course of treatment is 1-3 months.

With epilepsy with a slowdown in mental processes in complex therapy with anticonvulsants: for adults - in a dose of 500 to 1000 mg 3 times a day; children - in a dose of 250 to 500 mg 3-4 times a day. The course of treatment is up to 6 months.

With psycho-emotional overload, decreased mental and physical performance, to improve concentration and memorization: 250 mg 3 times a day.

For neurogenic urination disorders: for adults - in a dose of 500 to 1000 mg 2-3 times a day; children - at a dose of 250 to 500 mg 3 times a day (the daily dose is 25-50 mg / kg). The course of treatment is 1-3 months.

Children with various pathologies of the nervous system, depending on age, are recommended to take the drug up to 3000 mg per day.

The tactics of prescribing the drug: increasing the dose for 7-12 days, taking the maximum dose for 15-40 days and gradually reducing the dose until the drug is discontinued within 7-8 days.

The break between course doses of the drug, as for any other nootropic drug, is from 1 to 3 months.

Children with developmental delay: 500 mg 3-4 times a day. The course of treatment is 2-3 months.

For children with attention deficit hyperactivity disorder, depending on body weight, the drug is prescribed in an average therapeutic dose of 30 mg / kg per day, in the morning and in the afternoon.

The optimal dose is determined for each patient individually by selection with a gradual increase in the dose during the first 5-7 days. The course of treatment is 3-4 months.

Children with neurosis-like conditions (tics, stuttering, mainly in the clonic form): in a dose of 250 to 500 mg 3-6 times a day. The course of treatment is 1-4 months.

Taking into account the nootropic effect of the drug, its administration is carried out preferably in the morning and afternoon hours (up to 17 hours).

One tablet contains:

active substance: calcium hopantenate (calcium salt of hopantenic acid) - 250.0 mg; excipients: magnesium hydroxycarbonate - 46.8 mg; talc - 9.3 mg; calcium stearate - 3.1 mg; methylcellulose - 0.8 mg.

hypersensitivity to hopantenic acid and other components of the drug;

acute severe kidney disease;

pregnancy; breastfeeding period;

children's age up to 3 years.

Composition

One tablet contains:

active substance: calcium hopantenate (calcium salt of hopantenic acid) - 250.0 mg;

excipients: magnesium hydroxycarbonate - 46.8 mg; talc - 9.3 mg; calcium stearate - 3.1 mg; methylcellulose - 0.8 mg.

pharmachologic effect

The spectrum of action of hopantenic acid is associated with the presence of gamma-aminobutyric acid (GABA) in its structure. The mechanism of action is due to the direct effect of the drug on the GABAB-receptor-channel complex. Hopantenic acid has a nootropic and anticonvulsant effect. The drug increases the brain's resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability, activates mental and physical performance. Improves GABA metabolism in chronic alcohol intoxication and after ethanol withdrawal. Hopantenic acid is able to inhibit acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter.It causes inhibition of the pathologically increased gallbladder reflex and detrusor tone.

Pharmacokinetics

Hopantenic acid is rapidly absorbed from the gastrointestinal tract, penetrates the blood-brain barrier, the highest concentrations are created in the liver, kidneys, stomach wall and skin. The drug is not metabolized and is excreted unchanged within 48 hours: 67.5% of the dose taken - with urine, 28.5% - with feces.

Indications

cognitive impairment in organic brain lesions, including the consequences of neuroinfections, craniocerebral trauma and neurotic disorders;

extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system in combination with ongoing therapy;

as a corrector for side effects of neuroleptic drugs, with neuroleptic extrapyramidal syndrome (hyperkinetic and akinetic), as part of complex therapy for cerebral organic insufficiency in patients with schizophrenia; epilepsy with a slowdown in mental processes in complex therapy with anticonvulsants;

psycho-emotional overload, decreased mental and physical performance, to improve concentration and memorization;

neurogenic urinary disorders (Pollakiuria, urgency, urinary incontinence, enuresis);

children with developmental delay (mental, speech, motor or their combination), including against the background of previous perinatal encephalopathy and in children with various forms of cerebral palsy;

children with hyperkinetic disorders (attention deficit hyperactivity disorder);

children with neurosis-like conditions (tics, stuttering, mainly with a clonic form).

Contraindications

hypersensitivity to hopantenic acid and other components of the drug;

acute severe kidney disease;

pregnancy; breastfeeding period;

children's age up to 3 years.

special instructions

In conditions of long-term treatment, the simultaneous administration of the drug with other nootropic and stimulating agents is not recommended. In case of development of undesirable reactions such as allergic rhinitis, conjunctivitis, skin allergic reactions, the drug must be canceled. In the event of the development of adverse events from the central nervous system, it is necessary to reduce the dose of the drug. Taking into account the nootropic effect of the drug, its administration is carried out preferably in the morning and afternoon hours (up to 17 hours).

Method of administration and dosage